文献速递围术期管理与 ERAS急腹症与外科感染

凝血酶原复合物与血浆用于体外循环心脏术后凝血病及出血的随机临床试验

Prothrombin Complex Concentrate vs Plasma for Post-Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2022-01-01

单中心随机临床试验纳入100例体外循环心脏术后微血管出血且PT>16.6秒、INR>1.6的患者,比较凝血酶原复合物(PCC)与血浆。两组胸管引流量无显著差异,PCC组PT/INR改善更明显、术后红细胞输注率更低,总体安全性和疗效相似。

要点

  • PCC与血浆在术后胸管引流量上无显著差异
  • PCC组PT和INR纠正程度优于血浆组
  • PCC组治疗后术中红细胞输注率更低

核心结论

  • PCC与血浆在体外循环心脏术后凝血病中安全性和疗效总体相似。
  • PCC组术后红细胞输注更少、PT/INR纠正更好、避免异体输血可能性更高。

研究设计与样本

  • 单中心前瞻性随机临床试验,在高容量心脏外科中心进行。
  • 756例患者被接洽入组,553例随机,其中100例符合研究干预标准并接受治疗(血浆49例,PCC 51例)。
  • 入组患者年龄≥18岁,接受体外循环心脏手术,优先纳入复杂手术(如主动脉置换、多术式或再次胸骨切开)。

主要发现

  • 血浆组与PCC组胸管引流量中位数[IQR]分别为1022[799-1575] mL与937[708-1443] mL,无显著差异。
  • PCC组治疗后PT改善效应估计值为-1.37秒(95%CI -1.91至-0.84;P<.001),INR改善效应估计值为-0.12(95%CI -0.16至-0.07;P<.001)。
  • PCC组治疗后术中红细胞输注7/51例(13.7%),血浆组15/49例(30.6%),P=.04。
  • PCC组7/51例(13.7%)从术中至术后第1天结束避免异体输血,血浆组为0例。
  • 术后出血、输血或不良事件方面无显著差异。

关键数值与推荐

  • 研究干预标准:微血管出血过多、凝血酶原时间(PT)>16.6秒且国际标准化比值(INR)>1.6。
  • PCC剂量为15 IU/kg或最接近的标准剂量;血浆建议体积为10至15 mL/kg,取整至最接近单位。
  • 主要结局为术后从初始ICU入室至术后第1天午夜的胸管引流量。

临床怎么用

  • 对于体外循环心脏术后微血管出血且PT>16.6秒、INR>1.6的患者,PCC可作为血浆的替代选择。
  • PCC可能减少治疗后术中红细胞输注并提高避免异体输血的可能性,但需结合个体情况使用。

局限性

  • 单中心研究,仅100例患者接受研究干预,样本量有限。
  • 研究优先纳入复杂心脏手术患者,结果外推需谨慎。
  • 主要结局胸管引流量两组无显著差异,临床获益需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Post-cardiopulmonary bypass (CPB) coagulopathy and bleeding are among the most common reasons for blood product transfusion in surgical practices. Current retrospective data suggest lower transfusion rates and blood loss in patients receiving prothrombin complex concentrate (PCC) compared with plasma after cardiac surgery. OBJECTIVE: To analyze perioperative bleeding and transfusion outcomes in patients undergoing cardiac surgery who develop microvascular bleeding and receive treatment with either PCC or plasma. DESIGN, SETTING, AND PARTICIPANTS: A single-institution, prospective, randomized clinical trial performed at a high-volume cardiac surgical center. Patients were aged 18 years or older and undergoing cardiac surgery with CPB. Patients undergoing complex cardiac surgical procedures (eg, aortic replacement surgery, multiple procedures, or repeated sternotomy) were preferentially targeted for enrollment. During the study period, 756 patients were approached for enrollment, and 553 patients were randomized. Of the 553 randomized patients, 100 patients met criteria for study intervention. INTERVENTIONS: Patients with excessive microvascular bleeding, a prothombin time (PT) greater than 16.6 seconds, and an international normalized ratio (INR) greater than 1.6 were randomized to receive treatment with either PCC or plasma. The PCC dose was 15 IU/kg or closest standardized dose; the plasma dose was a suggested volume of 10 to 15 mL/kg rounded to the nearest unit. MAIN OUTCOMES AND MEASURES: The primary outcome was postoperative bleeding (chest tube output) from the initial postsurgical intensive care unit admission through midnight on postoperative day 1. Secondary outcomes were PT/INR, rates of intraoperative red blood cell (RBC) transfusion after treatment, avoidance of allogeneic transfusion from the intraoperative period to the end of postoperative day 1, postoperative bleeding, and adverse events. RESULTS: One hundred patients (mean [SD] age, 66.8 [13.7] years; 61 [61.0%] male; and 1 [1.0%] Black, 1 [1.0%] Hispanic, and 98 [98.0%] White) received the study intervention (49 plasma and 51 PCC). There was no significant difference in chest tube output between the plasma and PCC groups (median [IQR], 1022 [799-1575] mL vs 937 [708-1443] mL). After treatment, patients in the PCC arm had a greater improvement in PT (effect estimate, -1.37 seconds [95% CI, -1.91 to -0.84]; P < .001) and INR (effect estimate, -0.12 [95% CI, -0.16 to -0.07]; P < .001). Fewer patients in the PCC group required intraoperative RBC transfusion after treatment (7 of 51 patients [13.7%] vs 15 of 49 patients [30.6%]; P = .04); total intraoperative transfusion rates were not significantly different between groups. Seven (13.7%) of 51 patients receiving PCCs avoided allogeneic transfusion from the intraoperative period to the end of postoperative day 1 vs none of those receiving plasma. There were no significant differences in postoperative bleeding, transfusions, or adverse events. CONCLUSIONS AND RELEVANCE: The results of this study suggest a similar overall safety and efficacy profile for PCCs compared with plasma in this clinical context, with fewer posttreatment intraoperative RBC transfusions, improved PT/INR correction, and higher likelihood of allogeneic transfusion avoidance in patients receiving PCCs. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02557672.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Smith MM, Schroeder DR, Nelson JA, et al. Prothrombin Complex Concentrate vs Plasma for Post-Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial. JAMA Surg. 2022. PMID: 35767271. doi:10.1001/jamasurg.2022.2235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。